31 Oct 2026, 06:41 IST
Sun Pharmaceutical Industries Limited
HDFC Securities · BUY · target INR 2,180
The report says EBITDA grew 14% YoY on 12% sales growth, retains BUY and cuts FY27E/28E EPS by 4%/2% while revising target price to INR 2,180.
From HSIE Results Daily 31 Oct 26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.